Article
KIT as a therapeutic target in metastatic melanoma.
JAMA - 8 Jun 2011
Carvajal Richard D, Antonescu Cristina R, Wolchok Jedd D, Chapman Paul B, Roman Ruth-Ann, Teitcher Jerrold, Panageas Katherine S, Busam Klaus J, Chmielowski Bartosz, Lutzky Jose, Pavlick Anna C, Fusco Anne, Cane Lauren, Takebe Naoko, Vemula Swapna, Bouvier Nancy, Bastian Boris C, Schwartz Gary K
Abstract excerpt
CONTEXT: Some melanomas arising from acral, mucosal, and chronically sun-damaged sites harbor activating mutations and amplification of the type III transmembrane receptor tyrosine kinase KIT. We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease. OBJECTIVE: To assess clinical effects of imatinib mesylate in patients with melanoma harboring KIT alterations. DESIGN,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.